AOCNP Cancer Pharmacology and Chemotherapy 2

Question 1

Which targeted therapy is a monoclonal antibody that blocks the HER2 receptor in HER2-positive breast cancer?

Accepted Answer

Trastuzumab

Answer

Erlotinib

Answer

Imatinib

Answer

Bevacizumab

Question 2

Imatinib (Gleevec) revolutionized the treatment of CML by targeting:

Accepted Answer

The BCR-ABL tyrosine kinase

Answer

VEGF receptor

Answer

EGFR receptor

Answer

CD20 antigen

Question 3

Which toxicity is most uniquely associated with bleomycin that limits its cumulative dosing?

Accepted Answer

Pulmonary fibrosis

Answer

Nephrotoxicity

Answer

Cardiotoxicity

Answer

Hepatotoxicity

Question 4

VEGF inhibitor bevacizumab carries which unique risk compared to cytotoxic chemotherapy?

Accepted Answer

Arterial thromboembolic events, wound healing impairment, and GI perforation

Answer

Febrile neutropenia

Answer

Alopecia

Answer

Mucositis

Question 5

PARP inhibitors such as olaparib are most effective in tumors with defects in which repair pathway?

Accepted Answer

Homologous recombination (BRCA1/2 mutations)

Answer

Nucleotide excision repair

Answer

Mismatch repair

Answer

Base excision repair only

Question 6

Checkpoint inhibitors targeting PD-1 (e.g., pembrolizumab) cause a distinctive class of toxicities called:

Accepted Answer

Immune-related adverse events (irAEs)

Answer

Infusion-related reactions only

Answer

Cytokine release syndrome

Answer

Tumor lysis syndrome